In vitro comparison of cilofungin alone and in combination with other antifungal agents against clinical isolates of Candida species.
Cilofungin, a lipopeptide antifungal agent, was tested for in vitro activity alone and in combination with ketoconazole, itraconazole, flucytosine and amphotericin B against 102 clinical isolates of Candida species. At 48 hours all isolates of Candida albicans, Candida tropicalis, Candida paratropicalis and Candida glabrata were inhibited by less than or equal to 5 meg/ml of cilofungin. In contrast, the MIC90 for Candida krusei was 10 mcg/ml and for Candida parapsilosis greater than 40 mcg/ml. The interaction of combinations of cilofungin with amphotericin B, itraconazole, ketoconazole and flucytosine was additive or indifferent at 48 hours for 100%, 88%, 78% and 70% of all Candida species isolates, respectively. Overall, cilofungin demonstrated good activity in vitro against most Candida species isolates.
Smith
K R
KR
Department of Medicine, University of Alabama, Birmingham 35294.
Lank
K M
KM
Dismukes
W E
WE
Cobbs
C G
CG
D000666:Amphotericin B / Q000008:administration & dosage / Q000494:pharmacology; D000935:Antifungal Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects*; D002176:Candida albicans / Q000187:drug effects; D004359:Drug Therapy, Combination; D054714:Echinocandins; D005437:Flucytosine / Q000008:administration & dosage / Q000494:pharmacology; D017964:Itraconazole; D007654:Ketoconazole / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D010455:Peptides / Q000008:administration & dosage / Q000494:pharmacology; D010456:Peptides, Cyclic
D000935:Antifungal Agents; D054714:Echinocandins; D010455:Peptides; D010456:Peptides, Cyclic; D017964:Itraconazole; D000666:Amphotericin B; C042101:cilofungin; D005437:Flucytosine; D007654:Ketoconazole